[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
August 2005

Reexamination of the TEMPO Study—Reply

Andrew Siderowf, MD, MSCE; Shirley Eberly, MS; David Oakes, PhD; et al Ira Shoulson, MD; Parkinson Study Group TEMPO Steering Committee
Arch Neurol. 2005;62(8):1321. doi:10.1001/archneur.62.8.1321

In reply

We thank Dr Shults for his interest in the TEMPO study,1 which incorporated a randomized, delayed-start design to help differentiate short-term symptomatic effects of rasagiline from more durable, disease-modifying effects.2 As in the Coenzyme Q10 trial in early Parkinson disease,3 the total Unified Parkinson’s Disease Rating Scale (UPDRS) score was prespecified as the primary measure of efficacy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×